ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2157

Factors Associated with Clinical Remission of Skin Disease in Dermatomyositis

Paige Wolstencroft1, Lorinda Chung2, Shufeng Li1, Livia Casciola-Rosen3 and David Fiorentino4, 1Dermatology, Stanford University School of Medicine, Stanford, CA, 2Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, 3Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 4Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Cutaneous manifestations, dermatomyositis and outcomes

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Session Title: Muscle Biology, Myositis and Myopathies Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Quantitative estimates of the duration and severity of cutaneous disease are lacking for adult dermatomyositis (DM) patients. The Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) is a validated instrument that quantifies cutaneous disease activity (CDASI-a), and allows for objective assessments of disease severity. Our aims were to estimate the percentage of DM patients with clinically significant skin inflammation who achieve clinical remission (CR) of skin disease during a 3-year follow-up period and to examine the relationship between skin disease course and selected clinical variables.

 

Methods:

Adult DM patients (age >18 years) seen at our outpatient clinic between May 15, 2007 and October 28, 2016 were considered for this study. DM was diagnosed using Bohan/Peter criteria, or, for clinically amyopathic patients, Sontheimer criteria. Patients were included if their initial CDASI-a score was greater than or equal to 12, and they had a minimum of 2 scores recorded 3 or more months apart. CR was defined as a CDASI-a less than or equal to 5 with no individual erythema score >1 and no ulcerations. Univariable and multivariable logistic regression analysis was performed using age, race, gender, amyopathic status, DM-associated malignancy, baseline CDASI-a, disease duration at baseline, time until first systemic therapy, autoantibody phenotype (Mi-2, TIF-1gamma, SAE1, MDA5, NXP2 or Ro52), and medication exposure as covariates. For selected variables, Kaplan-Meier plots were created and log-rank analysis used to compare curves.

 

Results:

In total 74 patients met our inclusion criteria.  The median duration of follow-up was 17.5 (11-28) months, with a median of 4 (3-6) months between CDASI scores. Overall, 36% of patients were treated with mycophenolate mofetil (MMF), 38% with antimalarials, 39% with methotrexate and 24% with IVIG. Twenty-eight patients (38%) entered CR within 3 years, and the overall probability of CR was 0.43 after 36 months (Figure 1A). The probability of CR was significantly higher for patients without anti-MDA5 antibodies (Figure 1B) as 0/10 anti-MDA5 patients entered CR. Increased age (OR 1.07, 95% CI 1.02-1.12; P=0.01), DM-associated malignancy (OR 14.46, 95% CI 2.18-96.07; P=0.006) and MMF (OR 6.00, 95% CI 1.66-21.78; P=0.0064) were significantly associated with CR in multivariable regression analysis.

Conclusion:

CR was relatively uncommon in our population, and even less common among anti-MDA5 patients, despite the use of aggressive systemic therapy. The positive association between MMF and CR suggests that MMF should be considered a first line agent for DM skin disease, while our overall results highlight the need for new therapies to more effectively treat skin disease in DM. Increased age and DM-associated malignancy were both associated with positive cutaneous outcomes, which has important prognostic significance.

Layout%203.pdf


Disclosure: P. Wolstencroft, None; L. Chung, None; S. Li, None; L. Casciola-Rosen, None; D. Fiorentino, None.

To cite this abstract in AMA style:

Wolstencroft P, Chung L, Li S, Casciola-Rosen L, Fiorentino D. Factors Associated with Clinical Remission of Skin Disease in Dermatomyositis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/factors-associated-with-clinical-remission-of-skin-disease-in-dermatomyositis/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-associated-with-clinical-remission-of-skin-disease-in-dermatomyositis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences